Login / Signup

A pilot study of cabergoline for the treatment of metastatic breast cancer.

Ricardo L B CostaC A Santa-MariaD M ScholtensS JainL FlaumW J GradisharC V ClevengerV G Kaklamani
Published in: Breast cancer research and treatment (2017)
Cabergoline was well tolerated, and while the ORR was low, a small subset of patients experienced extended disease control.
Keyphrases
  • metastatic breast cancer
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • patient reported outcomes
  • smoking cessation